Clinical trial · Interventional
Sugammadex Given for the Reversal of Rocuronium Induced Neuromuscular Blockade Under Sevoflurane Anesthesia in Infants
Sugammadex Given for the Reversal of Deep Rocuronium Induced Neuromuscular Blockade Under Sevoflurane Anesthesia in Infants: A Retrospective Study
NCT02708056CI-TRIAL-00021363completedPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The objective of this study is to evaluate the efficacy and safety of sugammadex in reversing profound neuromuscular block induced by rocuronium in infant patients
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Cancer | Malignant Brain Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Sugammadex | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Sugammadex, Bridion
- description
- Drug were given intravenously by a anesthesiologist at the end of surgery
- interventionNames
- Drug: Sugammadex
Primary outcomes (1)
- measure
- The efficacy of sugammadex were assessed by using Train of four (TOF)
- timeFrame
- 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 1 Month
- Maximum age
- 12 Months
Show eligibility criteria text
Inclusion Criteria: * Patients between the ages of 1-12 month, * ASA physical status 1-3 who underwent elective brain cancer surgery during general anesthesia were included in the study Exclusion Criteria: * younger than 1month or older than 12 months. * hepatic or renal failure * A history of allergy to study medication
References
Publications (0)
Data not yet available
No reference posted for this study.